CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Income Statement [Abstract]
Net revenues	$ 127,321	$ 130,998	$ 375,554	$ 409,411	$ 537,840
Cost of revenues	32,092	29,749	95,724	85,979	114,867
Gross profit	95,229	101,249	279,830	323,432	422,973
Operating costs and expenses:
Research, development and clinical studies	53,623	51,956	168,754	151,265	206,085
Sales and marketing	57,964	41,395	167,621	124,029	173,658
General and administrative	41,887	32,509	124,609	94,683	132,753
Total operating costs and expenses	153,474	125,860	460,984	369,977	512,496
Operating income (loss)	(58,245)	(24,611)	(181,154)	(46,545)	(89,523)
Financial income (expenses), net	10,023	1,194	27,948	(2,743)	7,677
Income (loss) before income tax	(48,222)	(23,417)	(153,206)	(49,288)	(81,846)
Income tax	1,263	3,159	6,758	5,943	10,688
Net income (loss)	$ (49,485)	$ (26,576)	$ (159,964)	$ (55,231)	$ (92,534)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.46)	$ (0.25)	$ (1.51)	$ (0.53)	$ (0.88)
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.46)	$ (0.25)	$ (1.51)	$ (0.53)	$ (0.88)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	106,772,814	104,884,583	106,219,194	104,552,803	104,660,476
Weighted average number of ordinary shares used in computing diluted net income (loss) per share	106,772,814	104,884,583	106,219,194	104,552,803	104,660,476